Skip to Main Content

NISH (NITAG SUPPORT HUB) 3 - Malaria vaccines: Kenya

This Library Guide is a collection of useful documents & evidence on the efficacy, effectiveness and impact of the RTS,S/AS01 malaria vaccine to support NITAG members and other policy makers throughout Africa with making evidence-based recommendations.

Malaria vaccine

Organisation mondiale de la Santé, O. and World Health Organization, 2022. Malaria vaccine: WHO position paper–March 2022–Rapport mensuel des cas de dracunculose, janvier 2022. Weekly Epidemiological Record= Relevé épidémiologique hebdomadaire, 97(09), pp.60-78.
 
World Health Organization, 2022. WHO guidelines for malaria, 3 June 2022 (No. WHO/UCN/GMP/2022.01 Rev. 2). World Health Organization.
 
World Health Organization. 2021. Infographic of the RTS,S Malaria vaccine. A WHO recommended vaccine for added protection against malaria to improve child health, save lives and strengthen malaria control in Africa and in other regions with moderate to high malaria transmission.
 
World Health Organization. 2022. Malaria vaccine implementation programme.
 
Penny, M.A., Kelly, S.L., Shattock, A.J., Ross, A., Malinga, J., Winskill, P., Hogan, A., Mulongeni, P., Thompson, H., Verity, B. and Ghani, A.,2021. Modelled public health impact and cost effectiveness estimates of RTS,S/AS01 malaria vaccine in perennial and seasonal settings. WHO Guidelines for malaria.
 
Galactionova, K., Bertram, M., Lauer, J. and Tediosi, F., 2015. Costing RTS, S introduction in Burkina Faso, Ghana, Kenya, Senegal, Tanzania, and Uganda: a generalizable approach drawing on publicly available data. Vaccine, 33(48), pp.6710-6718.
 
World Health Organization. 2022. Q&A on the RTS,S malaria vaccine, the WHO vaccine recommendation and next steps.
 
Villanueva, G., Henschke, N., Hamel, C. and Buckley, B., Annex 9a: Grading of Recommendations, Assessment, Development, and Evaluation (GRADE) Evidence summary table. RTS, 1, p.1.
 
RTS,S/AS01 SAGE/MPAG Working Group. (2022). Full Evidence Report on the RTS,S/AS01 Malaria Vaccine. Zenodo. https://doi.org/10.5281/zenodo.6394605
 
Milligan P, & Moore K. (2022). Statistical report on the results of the RTS,S/AS01 Malaria Vaccine Pilot Evaluation 24 months after the vaccine was introduced (September 2021, v1.2). Zenodo. https://doi.org/10.5281/zenodo.6395806
 
Rts, S.C.T.P., 2015. Efficacy and safety of RTS, S/AS01 malaria vaccine with or without a booster dose in infants and children in Africa: final results of a phase 3, individually randomised, controlled trial. The Lancet, 386(9988), pp.31-45. doi: 10.1016/S0140-6736(15)60721-8
 
Tinto, H., Otieno, W., Gesase, S., Sorgho, H., Otieno, L., Liheluka, E., Valéa, I., Sing'oei, V., Malabeja, A., Valia, D. and Wangwe, A., 2019. Long-term incidence of severe malaria following RTS, S/AS01 vaccination in children and infants in Africa: an open-label 3-year extension study of a phase 3 randomised controlled trial. The Lancet Infectious Diseases, 19(8), pp.821-832.
 

PATH, Liverpool School of Tropical Medicine (Kenya), Malawi-Liverpool Wellcome Trust (Malawi), & University of Health and Allied Sciences (Ghana). (2022). Health Utilisation Study (HUS) Round 2 - cross-country report on findings from the Primary Child Caregiver cohort sample. Zenodo. https://doi.org/10.5281/zenodo.6395820

Chandramohan, D., Zongo, I., Sagara, I., Cairns, M., Yerbanga, R.S., Diarra, M., Nikiema, F., Tapily, A., Sompougdou, F., Issiaka, D. and Zoungrana, C., 2021. Seasonal malaria vaccination with or without seasonal malaria chemoprevention. New England Journal of Medicine, 385(11), pp.1005-1017. DOI: 10.1056/NEJMoa2026330